FCMT
IBB icon

Founders Capital Management (Texas)’s iShares Biotechnology ETF IBB Stock Holding History

Founders Capital Management (Texas)’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16K Hold
6
– – ﹤0.01% 401
2026
Q1 		$1.03K Hold
6
– – ﹤0.01% 372
2025
Q4 		$1.03K Hold
6
– – ﹤0.01% 382
2025
Q3 		$881 Hold
6
– – ﹤0.01% 370
2025
Q2 		$771 Hold
6
– – ﹤0.01% 360
2025
Q1 		$780 Hold
6
– – ﹤0.01% 347
2024
Q4 		$805 Hold
6
– – ﹤0.01% 343
2024
Q3 		$886 Hold
6
– – ﹤0.01% 350
2024
Q2 		$835 Hold
6
– – ﹤0.01% 351
2024
Q1 		$834 Hold
6
– – ﹤0.01% 339
2023
Q4 		$825 Hold
6
– – ﹤0.01% 364
2023
Q3 		$741 Sell
6
-300
-98% -$38.2K ﹤0.01% 384
2023
Q2 		$38.9K Hold
306
– – 0.03% 160
2023
Q1 		$40K Sell
306
-17,483
-98% -$2.29M 0.03% 154
2022
Q4 		$2.34M Hold
17,789
– – 1.76% 21
2022
Q3 		$2.08M Sell
17,789
-2,811
-14% -$349K 1.7% 22
2022
Q2 		$2.42M Sell
20,600
-2,205
-10% -$262K 1.91% 20
2022
Q1 		$3.48M Hold
22,805
– – 2.23% 17
2021
Q4 		$3.48M Sell
22,805
-116
-0.5% -$18K 2.23% 17
2021
Q3 		$3.71M Sell
22,921
-1,194
-5% -$201K 2.54% 12
2021
Q2 		$3.95M Sell
24,115
-290
-1% -$44.7K 2.57% 11
2021
Q1 		$3.67M Buy
24,405
+1,535
+7% +$244K 2.62% 16
2020
Q4 		$3.46M Buy
+22,870
New +$3.27M 2.45% 14
2020
Q1 		$433K Hold
4,020
– – 0.45% 32
2019
Q4 		$484K Buy
4,020
+749
+23% +$83.6K 0.37% 36
2019
Q3 		$325K Buy
3,271
+380
+13% +$39.8K 0.26% 44
2019
Q2 		$315K Buy
2,891
+480
+20% +$51.1K 0.28% 46
2019
Q1 		$270K Buy
2,411
+40
+2% +$4.39K 0.25% 49
2018
Q4 		$229K Buy
2,371
+80
+3% +$8.49K 0.24% 50
2018
Q3 		$279K Buy
2,291
+1,625
+244% +$191K 0.23% 55
2018
Q2 		$73K Sell
666
-774
-54% -$82.8K 0.06% 100
2018
Q1 		$154K Hold
1,440
– – 0.13% 84
2017
Q4 		$154K Hold
1,440
– – 0.13% 86
2017
Q3 		$160K Sell
1,440
-90
-6% -$9.62K 0.13% 89
2017
Q2 		$158K Hold
1,530
– – 0.14% 82
2017
Q1 		$150K Buy
+1,530
New +$146K 0.13% 87

Other funds holding IBB

WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return
CA
Cumberland Advisors Sarasota, Florida $284M AUM 27.11% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Founders Capital Management (Texas)'s IBB Position: Q2 2026 in Review

Founders Capital Management (Texas) held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 6 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #401.

Founders Capital Management (Texas) first reported a position in IBB in Q1 2017 and has held it in 36 quarters since. The position peaked at $3.95M in Q2 2021. 285 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Founders Capital Management (Texas) held 6 shares of iShares Biotechnology ETF worth $1.16K as of Q2 2026.
  • Founders Capital Management (Texas) left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #401 holding.
  • Founders Capital Management (Texas) first reported a position in iShares Biotechnology ETF in Q1 2017 and has held it in 36 quarters since.
  • Founders Capital Management (Texas)'s iShares Biotechnology ETF position peaked at $3.95M in Q2 2021.
  • 285 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.